Retisert (fluocinolone acetonide intravitreal implant) / EyePoint Pharma, Bausch Health 
Welcome,         Profile    Billing    Logout  

2 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Retisert (fluocinolone acetonide intravitreal implant) / Bausch Health, EyePoint Pharma
2007-003612-53: Multicenter Uveitis Steroid Treatment Trial

Ongoing
3
80
Europe
Retisert, Retisert, Retisert
National Institutes of Health, National Eye Institute
Non-infectious uveitis (inflammatory eye disease)
 
 
2011-001078-25: Long term follow-up clinical trial to the MUST trial which investigates which treatment of systemic steroid treatment and a steroid implant which is inserted into the eye gives the best visual outcome for patients with chronic eye inflammation.

Ongoing
3
31
Europe
Retisert, C05AA10, Retisert, Retisert
National Institute of Health, National Eye Institute, National Institute of Health, National Eye Institute
Non-infectious pan, intermediate and posterior uveitis (inflammatory eye disease)
 
 

Download Options